Nuvalent is a preclinical-stage biopharmaceutical company focused on creating targeted therapies for patients with cancer. It focuses on small molecule inhibitors of kinases and develops NVL-520, a brain-penetrant ROS1-selective inhibitor designed to inhibit wild-type ROS1 fusions and remain active in the presence of mutations conferring resistance to ROS1 inhibitors. The company also researches NVL-655, a brain-penetrant ALK-selective inhibitor designed to last in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors.